Biotechnology M&A » By The Online Investor Staff, updated Sat., Apr. 20, 3:22 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #23 of 83 |
Slide #23. Mast Therapeutics — Aires Pharmaceuticals, Inc.
Acquirer:
Mast Therapeutics (MSTX)
Acquiree:
Aires Pharmaceuticals, Inc.
Details:
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.
Savara is a biopharmaceutical company developing clinical-stage therapies for serious or life-threatening diseases. Co.'s key product candidate, AIR001, a sodium nitrite solution for inhalation via nebulization, is in Phase 2 clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure or heart failure with preserved systolic function. Co.'s other product candidate, Vepoloxamer, is a purified poloxamer 188, a nonionic, block copolymer comprised of a central linear chain of hydrophobic polyoxypropylene flanked on both sides by linear hydrophilic polyoxyethylene chains.
Open the MSTX Page at The Online Investor »
|
|||||||||
Open the MSTX Page at The Online Investor (in a new window) »
 Free MSTX Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
